To explore the consistency between result of PTC drug screening tests and actual clinical outcome for patients with advanced malignancy.
18 to 75 years old, regardless of gender.
Score of nutrition risk screening 2002 (NRS2002) is less than 3, NRS20023.
Advanced and unresectable malignancy confirmed by biopsy diagnosis.
Able to tolerate anti-tumor treatment, and without serious cardiopulmonary and other underlying diseases.
Pregnant or lactating women.
Have Participated other clinical trials in six months.
Severe liver dysfunction.
Severe renal dysfunction.
Cancer patients with malignant effusion, above 18 years of age, at Tongji Hospital, Tongji Medical College of HUST
Case-only
Prospective
Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing.
Diagnostic testFresh malignant effusion samples were collected from advanced malignancy patients for PTC drug sensitivity testing, then assess the accuracy of this diagnostic test by combination and analysis with final clinical outcome.
Complete Response (CR)
Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Length is measured in millimeters, refers to RECIST 1.1.
Partial Response (PR)
At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Length is measured in millimeters, refers to RECIST.1.1.
Progressive Disease (PD)
At least a 20% increase in the sum of diameters of taraet lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm (the appearance of one or more new lesions is also considered progression). Length is measured in millimeters, refers to RECIST 1.1.
Stable Disease (SD)
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Length is measured in millimeters, refers to RECIST 1.1.
Click on the lead sponsor to view all of their trials.
